- Conditions
- Pruritus
- Interventions
- Cervical Traction Device
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2569–2592
of 5,327
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Solid Tumors of Metastatic Disease
- Interventions
- Radiation Therapy, Systemic Therapy
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 9
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
- Conditions
- Polypharmacy, Care Transitions, Geriatric Syndromes
- Interventions
- Shed-Meds: A Patient-Centered Deprescribing Intervention
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pancreatic Cancer
- Interventions
- recombinant interferon alfa, cisplatin, fluorouracil, radiation therapy, Resection of tumor
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Binimetinib, Docetaxel, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Stanford, California • Lecanto, Florida + 9 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule
- Drug
- Lead sponsor
- Anu Sharma
- Other
- Eligibility
- 21 Years to 59 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab Soravtansine-gynx, Olaparib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 6
- States / cities
- Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Congenital Adrenal Hyperplasia (CAH)
- Interventions
- Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- La Jolla, California • Shreveport, Louisiana • Detroit, Michigan
- Conditions
- Neoplasms
- Interventions
- CC-90011, Nivolumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • New York, New York • Canton, Ohio + 5 more
- Conditions
- Breast Cancer
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hematological Malignancies
- Interventions
- fostamatinib
- Drug
- Lead sponsor
- Stefanie Sarantopoulos, MD, PhD.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SAR425899
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
- Conditions
- GIST and CML
- Interventions
- imatinib mesylate
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- PEGPH20, Nab-paclitaxel, Gemcitabine, Dexamethasone, Enoxaparin
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more
- Conditions
- Sphingomyelin Lipidosis
- Interventions
- GZ402665
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
- Interventions
- MGA271
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 12
- States / cities
- Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
- Conditions
- CDD
- Interventions
- Fenfluramine Hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
- Interventions
- PS-341 (VELCADE), Temozolomide, immunoenzyme technique
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
- Interventions
- Melphalan/HDS, Cisplatin and Gemcitabine
- Combination Product · Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Columbus, Ohio • Memphis, Tennessee
- Conditions
- Asthma
- Interventions
- Placebo ELLIPTA inhaler, Questionnaire
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more
- Conditions
- Obsessive - Compulsive Disorder
- Interventions
- ATTN201 - Low Intensity Focused Ultrasound
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer
- Interventions
- Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more